Fibrocell Science (FCSC) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access FCSC Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Fibrocell Science balances growth, leverage, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2019)
(Jun 30 2019) (Mar 31 2019) (Dec 31 2018) (Sep 30 2018)
Assets
Cash & cash equivalent6.77
Cash & Short-term Investments6.00
Accounts receivable2.53
Other Current Assets8.12
Prepaid Expense And Other Assets Current1.26
Total Current Assets18.68
Equipment/Property/Plant Net1.42
Other Assets, Noncurrent7.73
Total Assets27.83
Liabilities
Accounts Payable, Current AC1.64
Accrued Liabilities, Current1.76
Other Liabilities, Current0.27
Accrued Income Taxes, Current TA0.00
Deferred Rent Credit, Current DE0.00
Total Current Liabilities3.67
Total Long-term Debt0.00
Derivative Liability, Noncurrent DE6.08
Deferred Rent Credit, Noncurrent DE0.00
Other liabilities, Noncurrent7.34
Total Liabilities17.09
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock198.94
Retained Earnings / Accumulated Deficit-188.20
Other Equity-0.05
Common Stockholder's Equity10.70
Total Stockholder's Equity10.70
Liabilities & Stockholder's Equity27.83
4 historic quarters locked

Sign in to unlock the full Fibrocell Science balance sheet history.

About FCSC Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.